Crohn’s Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
Conventional agents (e.g., immunosuppressants, 5-ASAs) have long been used to treat pediatric Crohn’s disease (CD). Among the TNF-α inhibitors, Janssen/Merck’s Remicade and AbbVie/Eisai’s Humira are the most commonly used biologics in moderate to severe pediatric CD. The newer drugs (i.e., Takeda’s Entyvio and Janssen’s Stelara), approved for adult CD, offer alternative treatment options, especially for TNF-α refractory patients; however, these drugs are not approved in pediatric CD. Still, given the limited treatment options for pediatric CD patients who fail TNF-α inhibitors, physicians may turn to these novel therapies for some patients. Indeed, the availability of these newer agents will likely make the treatment landscape more complex.
QUESTIONS ANSWERED:
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric CD patients?
- How have Entyvio and Stelara been integrated into the treatment algorithm?
- What proportion of pediatric CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of pediatric CD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated pediatric patients with CD?
PRODUCT DESCRIPTION:
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
